DRMA vs ARTV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 22, 2026

DRMA

36.9
AI Score
VS
ARTV Wins

ARTV

46.7
AI Score

Investment Advisor Scores

DRMA

37score
Recommendation
SELL

ARTV

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DRMA ARTV Winner
Net Income -4.81M -28.72M DRMA
Operating Income -4.94M -30.67M DRMA
ROE -138.0% 17.7% ARTV
ROA -90.5% -27.3% ARTV
Total Assets 5.32M 105.11M ARTV
Cash 4.41M 53.50M ARTV
Current Ratio 3.40 6.53 ARTV
Free Cash Flow -5.01M -50.69M DRMA

Relative Price Performance (Last 90 Days)

DRMA 1M: +12.7% · 3M: +14.5% ARTV 1M: +7.9% · 3M: +36.8%

Current Technical Phase

DRMA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 57

RSI (14): 57.1 · Price: $1.42

ARTV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (13.9% over 20 days), RSI 51

RSI (14): 50.8 · Price: $10.93

Fundamentals Snapshot

Metric DRMA ARTV
Market Cap
Forward P/E -1.0 -4.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% -1.0%
Gross Margin
Operating Margin 0.0% 0.0%
EPS -4.20 -3.08
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ARTV is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.